Orville Kolterman - Concepedia

Author

Orville Kolterman

Also Known As

B. Rolin, D. Ryan, Kolterman, Orville, L. Hilsted, O G Kolterman, O Kolterman, O. G. KOLTERMAN, O. G. Kolterman, O. KOLTERMAN, O. Kolterman

163

Publications

14.1K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Health University of California San Diego Amplyx Pharmaceuticals (United States)University of Chicago University of Colorado Denver

About

Orville Kolterman is an author at University of Colorado Health specializing in medicine, diabetes, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	53	4.8K
2	Health Sciences	29	40	4K
3	Biochemistry	14	14	908
4	Natural Sciences	1	1	28
5	Public Health	1	1	69

Orville Kolterman

118

Publications

13K

Citations

H-Index

Page 1

	Year	Citations
Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. Orville Kolterman, J Insel, Mark Saekow, Journal of Clinical Investigation	1980	675
Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. Orville Kolterman, R S Gray, Justin W. Griffin, Journal of Clinical Investigation Noninsulin-dependent Diabetes MellitusType IiInsulin SignalingObesityMetabolic Syndrome	1981	635
Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes Orville Kolterman, John B. Buse, Mark Fineman, The Journal of Clinical Endocrinology & Metabolism	2003	551
Mechanisms of Insulin Resistance in Aging Raymond Fink, Orville Kolterman, Jennifer J. Griffin, Journal of Clinical Investigation	1983	550
The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus W. Timothy Garvey, Jerrold M. Olefsky, Justin W. Griffin, Diabetes	1985	467
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus Orville Kolterman, Dennis Dong Hwan Kim, Larry Z. Shen, American Journal of Health-System Pharmacy	2005	434
Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes Jerrold M. Olefsky, Orville Kolterman The American Journal of Medicine Insulin ResistanceObesityMetabolic SyndromeDiabetesPhysiology	1981	305
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial Robert E. Ratner, Richard A. Dickey, Mark Fineman, Diabetic Medicine	2004	303
Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes Priscilla Hollander, Philip T. Levy, Mark Fineman, Diabetes Care	2003	299
Role of Hyperglucagonemia in Maintenance of Increased Rates of Hepatic Glucose Output in Type II Diabetics Alain Baron, Linda Schaeffer, Paul Shragg, Diabetes	1987	299

Page 1